Medication info

Metritat Tablet 15/850 mg

Prescription medicationTabletExpired
Ingredient · strength
Pioglitazone Hydrochloride›16.53mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Seoul Pharmacy Co., Ltd.
Appearance
White to grayish-white oblong film-coated tablet
Packaging
30 tablets (10 tablets/PTP*3)
Approval status
Expired

MFDS item code 201902717 · Approved 2019.04.29

This product's status changed to Expired on 2024.04.29. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of blood glucose control in type 2 diabetes
Who uses it
Adults
Adult dosage
For the treatment of patients with type 2 diabetes, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding the maximum doses of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with metformin or pioglitazone monotherapy: The dose should be based on the dose of metformin or pioglitazone currently being taken. Start with 1 tablet of this medicine daily and gradually adjust the dose after evaluating the adequacy of the treatment response. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this medicine may start at the doses of pioglitazone and metformin they were previously receiving. 3. Patients with renal impairment: All dose adjustments should be based on careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not have their dose increased to the maximum dose of this medicine. This medicine should generally be administered in divided doses with meals, which may reduce gastrointestinal adverse reactions caused by metformin. Sufficient time is needed to evaluate the adequacy of the treatment response. Ideally, the response to treatment should be evaluated using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1C reflects blood glucose levels over the past 2 - 3 months. In clinical use of this medicine, if glycemic control measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) to evaluate changes in HbA1C is recommended.

Ingredients

Manufacturer
Seoul Pharmacy Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in type 2 diabetes

  • Insulin-independent diabetes
  • type 2 diabetes
  • blood sugar control disorder
View approved original text

This medication is used in conjunction with dietary and exercise therapy to help control blood sugar in patients with type 2 diabetes. It is administered when blood sugar control is insufficient with either metformin or pioglitazone monotherapy, or as a substitute for combining the two medications. Management of type 2 diabetes should include nutritional counseling and, if necessary, weight loss and regular exercise, as these lifestyle improvements are crucial for maintaining the effectiveness of drug therapy. Therefore, this medication is used to effectively improve blood sugar control in type 2 diabetes.

Dosage and Administration

Adult dosage

For the treatment of patients with type 2 diabetes, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding the maximum doses of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with metformin or pioglitazone monotherapy: The dose should be based on the dose of metformin or pioglitazone currently being taken. Start with 1 tablet of this medicine daily and gradually adjust the dose after evaluating the adequacy of the treatment response. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this medicine may start at the doses of pioglitazone and metformin they were previously receiving. 3. Patients with renal impairment: All dose adjustments should be based on careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not have their dose increased to the maximum dose of this medicine. This medicine should generally be administered in divided doses with meals, which may reduce gastrointestinal adverse reactions caused by metformin. Sufficient time is needed to evaluate the adequacy of the treatment response. Ideally, the response to treatment should be evaluated using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1C reflects blood glucose levels over the past 2 - 3 months. In clinical use of this medicine, if glycemic control measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) to evaluate changes in HbA1C is recommended.

Precautions

This medication is an antidiabetic drug that helps control blood sugar levels. However, it should not be used in patients with poor kidney function or severe heart failure. Rarely, this medication can cause a serious side effect called lactic acidosis, which is an excessive accumulation of lactic acid in the body leading to a dangerous condition. Lactic acidosis may present with symptoms such as vomiting, abdominal pain, muscle pain, shortness of breath, and weakness, and if these symptoms appear, the doctor should be notified immediately. Patients with poor liver function should also avoid using this medication, and excessive alcohol consumption should be avoided. In addition, it may put a strain on the heart, so special caution is needed if there are symptoms of heart failure or heart disease. While taking this medication, regular kidney and liver function tests should be conducted, and blood sugar levels should be consistently monitored. Pregnant or breastfeeding women should not use this medication. Safety and efficacy have not been established in children, so it should not be administered to them. If symptoms of heart failure such as sudden weight gain, swelling, or shortness of breath occur during treatment, a doctor should be consulted immediately. Additionally, there may be interactions when taken with other medications, so it is essential to discuss all current medications with a doctor or pharmacist. When undergoing surgery or imaging tests, this medication should be temporarily discontinued based on the doctor's instructions. In case of overdose, consult a medical institution immediately for appropriate treatment.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • fatigue
  • myalgia
  • dyspnea
  • weakness
  • abdominal pain
  • hypothermia
  • hypotension
  • resistant bradyarrhythmia
Show 47 more
  • upper respiratory infection
  • diarrhea
  • complex edema
  • peripheral edema
  • headache
  • nausea
  • urinary tract infection
  • sinusitis
  • dizziness
  • lower limb edema
  • weight gain
  • myalgia
  • dental disorder
  • worsening of diabetes
  • pharyngitis
  • anemia
  • vision reduction
  • liver failure
  • congestive heart failure
  • dyspepsia
  • insomnia
  • dry mouth
  • constipation
  • abdominal bloating
  • gastroesophageal reflux disease
  • intragastric air retention
  • increased serum creatinine
  • increased serum urea
  • macular edema
  • fracture
  • anemia
  • abnormal blood sugar
  • gastroenteritis
  • failed blood sugar control
  • hypoxia
  • dehydration
  • abnormal liver function
  • urinary disorders
  • urgency
  • recurrence of bladder cancer
  • liver damage
  • abnormal liver test results
  • liver function failure
  • fluid retention
  • fluid accumulation
  • weight gain
  • decreased serum vitamin B12

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is best to keep it at room temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

White to grayish-white oblong film-coated tablet

Package unit

30 tablets (10 tablets/PTP*3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.